Publications by authors named "Nathalie Dhedin"

The impact of hydroxyurea (HU) on the ovarian reserve of female patients with sickle cell disease (SCD) remains poorly elucidated. Only direct histological analysis of ovarian follicle density can effectively evaluate HU's effect on ovarian reserve. By analyzing digitized slides of ovarian tissue from girls and young women with SCD who underwent ovarian tissue cryopreservation (OTC) before hematological stem cell transplantation, we meticulously counted follicles and categorized them based on their growth stage.

View Article and Find Full Text PDF

Conditioning regimen prior to hematopoietic stem cell transplantation have an impact on patient fertility through the use of gonadal irradiation and/or bifunctional alkylating agents. Their impact on fertility depends mainly on the dose used and, in women, on age at the time of treatment. All patients should benefit before treatment from a consultation informing them of the potential impact on fertility and of fertility preservation techniques.

View Article and Find Full Text PDF

In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative-related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.

View Article and Find Full Text PDF

Purpose: To describe the experience of performing ovarian tissue cryopreservation (OTC) before hematopoietic stem cell transplantation (HSCT), among girls/women with severe sickle cell disease (SCD)(SS or S/β-thalassemia) who are, besides the usual surgical risk, at risk of SCD-related complications during the fertility preservation procedure for improving their counseling and management.

Methods: This retrospective study included 75 patients (girls/women) with SCD who have had OTC before myeloablative conditioning regimen (MAC) for HSCT. Characteristics of patients and data on OTC, ovarian status follow-up, and results of ovarian tissue transplantation (OTT) were collected in medical records.

View Article and Find Full Text PDF

The genetic diversity of the human leukocyte antigen (HLA) system was shaped by evolutionary constraints exerted by environmental factors. Analyzing HLA diversity may allow understanding of the underlying pathways and offer useful tools in transplant setting. The aim of this study was to investigate the HLA haplotype diversity in patients with sickle cell disease (SCD,  = 282) or β-thalassemia (β-Thal,  = 60), who received hematopoietic cell transplantation (HCT) reported to Eurocord and the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the clinical and immune characteristics of human parvovirus B19 (B19V) infections in patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT), reporting on cases from 2010 to 2021.* -
  • A total of 35 B19V infections were identified in 33 patients, with a median time from transplant to first positive PCR test being 6.9 months, and the most common symptoms including hematological impairment, rash, and fever.* -
  • The findings highlight that B19V can lead to diverse and atypical clinical manifestations, suggesting that the virus is often under-diagnosed due to its varied presentation; targeted tissue PCR may aid in
View Article and Find Full Text PDF

THERAPEUTIC APPROACHES IN SICKLE CELL DISEASE. Sickle cell disease, the most common genetic disease in France, is still burdened with morbidity and early mortality before the age of 50. When the first-line treatment, hydroxyurea, is insufficient or in the case of organic damage(s) (in particular cerebral vasculopathy), a therapeutic intensification must be considered.

View Article and Find Full Text PDF
Article Synopsis
  • The role and timing of allogeneic hematopoietic stem cell transplantation (HSCT) in treating acute myelogenous leukemia (AML) have been debated for decades, with reliance on the European LeukemiaNet classification for treatment strategies.
  • A study found that HSCT significantly improved overall survival for intermediate- and poor-risk AML patients, particularly younger patients, while showing low cumulative incidence rates for older groups due to factors like comorbidities and eligibility.
  • With increasing access to various donor types, including haploidentical ones, the role of HSCT in AML treatment may evolve, potentially increasing transplant numbers in adult patients.
View Article and Find Full Text PDF

Weekly blood Toxoplasma gondii DNA screening using real-time quantitative polymerase chain reaction (qPCR) has been implemented in all allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients at our hospital. We retrospectively analyzed the consequences of a positive blood qPCR in the management of Toxoplasma infection (TI) and disease (TD).From 2011 to 2020, 52 (4.

View Article and Find Full Text PDF

Allogeneic hematopoietic stem cell transplantation (alloSCT) is curative for severe inborn errors of immunity (IEIs), with recent data suggesting alloSCT in adulthood is safe and effective in selected patients. However, questions remain regarding the indications for and optimal timing of transplant. We retrospectively compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs.

View Article and Find Full Text PDF

Purpose: Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH). However, sMNs lack specific predictors, dedicated surveillance measures, and early therapeutic interventions.

Patients And Methods: We studied a multicenter, retrospective cohort of 1,008 patients (median follow-up 8.

View Article and Find Full Text PDF
Article Synopsis
  • The text outlines guidelines for fertility preservation (FP) in patients undergoing cancer treatment, emphasizing the importance of informing reproductive-aged individuals about the risk of gonadotoxicity from treatments.
  • It recommends specific FP strategies based on age and treatment type, such as oocyte cryopreservation for women and sperm cryopreservation for men, with additional options for higher-risk cases.
  • The choice of FP method should ultimately be made by the patient, considering their specific circumstances and treatment plans.
View Article and Find Full Text PDF

BK polyomavirus (BKPyV) can cause hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (allo-HCT). Recent evaluation of BKPyV HC (BKHC) incidence and risk factors are scarce. We conducted a retrospective single-center study on a recent allo-HCT cohort over 3 years in a referral academic hospital for hematological malignancies.

View Article and Find Full Text PDF

Purpose: In the acute lymphoblastic leukemia (ALL) landscape, adolescents and young adults (AYA) often present high-risk diseases and increased chemotherapy-related toxicity. Studies analyzing the outcomes of AYA after hematopoietic stem cell transplantation (HSCT) are scarce. Our study aimed to compare the outcomes of children and AYA with ALL after HSCT and to determine the factors influencing potential differences.

View Article and Find Full Text PDF

Adolescents and young adults (AYAs) represent a challenging group of acute lymphoblastic leukaemia (ALL) patients with specific needs. While there is growing evidence from comparative studies that this age group profits from intensified paediatric-based chemotherapy, the impact and optimal implementation of haematopoietic stem cell transplantation (HSCT) in the overall treatment strategy is less clear. Over recent years, improved survival rates after myeloablative allogeneic HSCT for ALL have been reported similarly for AYAs and children despite differences in transplantation practise.

View Article and Find Full Text PDF

Infertility in adolescents and young adult (AYA) survivors of malignant disease remains a major long-term adverse effect, but semen collection for fertility preservation in fertility centers is not always feasible and makes AYAs uncomfortable. We evaluated the feasibility of collecting sperm samples on the ward versus in fertility centers. Consecutive hospitalized AYA-aged male patients in the Hematology AYA unit (Saint-Louis Hospital, France) between August 2010 and June 2016 with hematological disease and indication of semen collection ( = 95) were included in this retrospective study.

View Article and Find Full Text PDF